Zai Lab Stock News

NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as a potential best-in-class tetracycline

NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as a potential best-in-class tetracycline NUZYRA is Zai Labs fourth new product approval and the first outside oncology SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused,

Zai Lab (NASDAQ:ZLAB) had its target price trimmed by JPMorgan Chase & Co. from $189.00 to $136.00 in a research note released on Wednesday morning, PriceTargets.com reports. The firm currently has an overweight rating on the stock. Several other research firms also recently weighed in on ZLAB. Zacks Investment Research downgraded shares of Zai Lab [] The post Zai Lab (NASDAQ:ZLAB) Price Target Lowered to $136.00 at JPMorgan Chase & Co. appeared first on ETF Daily News .

The China National Medical Products Administration (NMPA) has approved Zai Lab Limited's (NASDAQ: ZLAB) Nuzyra (omadacycline), a novel antibiotic with both oral and intravenous (IV) formulations. T

The stock price of Zai Lab Ltd (NASDAQ: ZLAB) increased by over 3% pre-market today. This is why it happened.

The threat of a forced delisting is weighing heavily on these two Chinese biotech stocks.

The threat of a forced delisting is weighing heavily on these two Chinese biotech stocks.

The threat of a forced delisting is weighing heavily on these two Chinese biotech stocks.

The U.S.-listed Chinese stocks with the most American ownership don't include many of the big names familiar to Wall Street, according to Morgan Stanley.

SVB Leerink reiterated their buy rating on shares of Zai Lab (NASDAQ:ZLAB) in a report released on Sunday morning, Analyst Price Targets reports. ZLAB has been the topic of several other reports. Sanford C. Bernstein started coverage on shares of Zai Lab in a research note on Tuesday, October 12th. They issued a market perform []

Analysts expect Zai Lab Limited (NASDAQ:ZLAB) to post sales of $55.21 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Zai Labs earnings. The lowest sales estimate is $46.50 million and the highest is $62.80 million. The firm is scheduled to announce its next quarterly earnings results []

Zai Lab Limited (NASDAQ:ZLAB) Director Peter Wirth acquired 4,000 shares of the firms stock in a transaction that occurred on Wednesday, December 8th. The shares were bought at an average price of $71.36 per share, with a total value of $285,440.00. The transaction was disclosed in a document filed with the SEC, which is available []

Zai Lab Limited (NASDAQ:ZLAB) Director Peter Wirth acquired 4,000 shares of the companys stock in a transaction that occurred on Wednesday, December 8th. The stock was acquired at an average cost of $71.36 per share, for a total transaction of $285,440.00. The transaction was disclosed in a legal filing with the SEC, which is accessible []

Wall Street analysts expect Zai Lab Limited (NASDAQ:ZLAB) to announce earnings per share (EPS) of ($1.65) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Zai Labs earnings. The lowest EPS estimate is ($1.82) and the highest is ($1.45). The firm is expected to issue its next quarterly earnings []

Wall Street brokerages expect that Zai Lab Limited (NASDAQ:ZLAB) will report $55.21 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Zai Labs earnings. The lowest sales estimate is $46.50 million and the highest is $62.80 million. The business is expected to announce its next earnings report [] The post Zai Lab Limited (NASDAQ:ZLAB) Expected to Announce Quarterly Sales of $55.21 Million appeared first on ETF Daily News .